Subanalysis of Phase III ARISTOTLE trial of Eliquis® (apixaban) demonstrated consistent results versus warfarin in patients with NVAF with or without valvular heart disease
3 September 2013 | By Pfizer
Data show consistent results in reductions in stroke or systemic embolism, fewer major bleeding events, and reductions in all-cause death...